Background: POEMS syndrome is a devastating syndrome, characterized by peripheral neuropathy, organomegaly, endocrinopathy, monoclonal plasma cells, skin changes, papilledema, volume overload, sclerotic bone lesions, thrombocytosis, & high VEGF. We noted an unexpectedly high transplant related morbidity, which we have since postulated to be ES.

Methods: 30 patients with POEMS were treated with PBSCT at Mayo Clinic Rochester. We retrospectively studied outcomes, with an emphasis on treatment related morbidity. Two definitions of ES were used: Spitzer (BMT 2001) and Maiolino (BMT 2003).

Results: Two-thirds were male. Median age was 48, range 20–70. Time from first symptoms and diagnosis was 26 and 4 months, respectively. To mobilize stem cells, CTX/G-CSF was used in 5 & G-CSF in the remainder. Conditioning was Mel200 (n=19), Mel140 (n=10), and BEAM (n=1). Post-transplant 15 had GM-CSF begun day+6. Only 10% remained outpatient, and median time to discharge from hospital was transplant day 17 (range 0–175). Factors predicting for later dismissal included age (p=0.04), abnormal CXR 7 to 17 days post transplant (p<0.0001), & bolus corticosteroids (CS) beyond day 12 post-transplant (p=0.006). Ninety-three percent had fever, although only 9 had bacteremia. Eight satisfied criteria for ES according to Spitzer and 14 according to Maiolino. Another 3 patients received steroid bolus days 8, 12, and 11 for presumed ES but did not meet criteria because of delayed ANC recovery (days 16, 18, and 20, respectively). Of the 5 patients requiring endotracheal intubation, 3 satisfied Maiolino’s criteria for ES. Although these 3 received bolus CS during their course, administration was delayed at 18, 14, and 18 days. The patient whose CS bolus antedated intubation only received prednisone 30 mg/day. In toto, fourteen patients received bolus CS (daily doses between 20 and 1200 mg prednisone equivalents) commencing day 8 to 59. Those 7 patients who received CS before day 13 did better than the 7 who received them day 13 or later (Table).

Conclusions: It is essential to recognize that nearly 50% of patients satisfied formal criteria for ES as defined by Maiolino. In these patients ES may run a self-limited course or lead to catastrophe.

No Steroid (n=16)Steroid ≤ D12 (n=7)Steroid > D12 (n=7)P
*Engraftment syndrome according to definition of Maiolino (M) or of Spitzer (S). 
ES M / S, n* 5 / 2 4 / 4 5 / 2 NA 
Wt change, % 0.6 (−.4.2–6.7) 6.7 (3.6–27.2) 11.2 (–2.1–23.2) 0.005 
Rash, % 27 71 43 0.13 
Diarrhea, % 73 86 86 0.71 
Tmax, C 39 (37.8–41) 40.1 (39–41.1) 38.9 (38.7–40.8) 0.08 
1st fever, day 10 (6–15) 8 (7–9) 12 (8–146) 0.007 
Abn CXR1, % 13 71 71 0.03 
Ventilator, % 14 71 0.004 
First WBC, day 12 (8–21) 14 (12–14) 14 (12–17) 0.03 
ANC500, day 15 (12–29) 16 (14–115) 18 (15–45) 0.08 
PLT20, day 12 (8–41) 20 (11–115) 24 (9–170) 0.05 
PLT50, day 15 (11–192) 32 (16–115) 56 (13–551) 0.03 
RBCs, units 3 (2–8) 6 (4–31) 11 (6–64) 0.0008 
PLTS, aph. units 2 (1–9) 9 (4–51) 18 (4–60) 0.0004 
Hosp dsm, day 15 (13–36) 21 (15–69) 41 (16–175) 0.009 
No Steroid (n=16)Steroid ≤ D12 (n=7)Steroid > D12 (n=7)P
*Engraftment syndrome according to definition of Maiolino (M) or of Spitzer (S). 
ES M / S, n* 5 / 2 4 / 4 5 / 2 NA 
Wt change, % 0.6 (−.4.2–6.7) 6.7 (3.6–27.2) 11.2 (–2.1–23.2) 0.005 
Rash, % 27 71 43 0.13 
Diarrhea, % 73 86 86 0.71 
Tmax, C 39 (37.8–41) 40.1 (39–41.1) 38.9 (38.7–40.8) 0.08 
1st fever, day 10 (6–15) 8 (7–9) 12 (8–146) 0.007 
Abn CXR1, % 13 71 71 0.03 
Ventilator, % 14 71 0.004 
First WBC, day 12 (8–21) 14 (12–14) 14 (12–17) 0.03 
ANC500, day 15 (12–29) 16 (14–115) 18 (15–45) 0.08 
PLT20, day 12 (8–41) 20 (11–115) 24 (9–170) 0.05 
PLT50, day 15 (11–192) 32 (16–115) 56 (13–551) 0.03 
RBCs, units 3 (2–8) 6 (4–31) 11 (6–64) 0.0008 
PLTS, aph. units 2 (1–9) 9 (4–51) 18 (4–60) 0.0004 
Hosp dsm, day 15 (13–36) 21 (15–69) 41 (16–175) 0.009 

Author notes

Disclosure: No relevant conflicts of interest to declare.

Sign in via your Institution